169 related articles for article (PubMed ID: 38244586)
1. α-Hederin promotes ferroptosis and reverses cisplatin chemoresistance in non-small cell lung cancer.
Han S; Yang X; Zhuang J; Zhou Q; Wang J; Ru L; Niu F; Mao W
Aging (Albany NY); 2024 Jan; 16(2):1298-1317. PubMed ID: 38244586
[TBL] [Abstract][Full Text] [Related]
2. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis.
Han B; Liu Y; Zhang Q; Liang L
J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803
[TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
Song Z; Jia G; Ma P; Cang S
Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830
[TBL] [Abstract][Full Text] [Related]
4. Regulatory mechanism of α-hederin upon cisplatin sensibility in NSCLC at safe dose by destroying GSS/GSH/GPX2 axis-mediated glutathione oxidation-reduction system.
Wu Y; Wang D; Lou Y; Liu X; Huang P; Jin M; Huang G
Biomed Pharmacother; 2022 Jun; 150():112927. PubMed ID: 35398749
[TBL] [Abstract][Full Text] [Related]
5. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis.
Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R
Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246
[TBL] [Abstract][Full Text] [Related]
6. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
7. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of METTL14-mediated m
Gong S; Wang S; Shao M
J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
[TBL] [Abstract][Full Text] [Related]
10. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
[TBL] [Abstract][Full Text] [Related]
11. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
12. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
13. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
15. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
16. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
Ma P; Han W; Meng C; Tan X; Liu P; Dong L
Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
[TBL] [Abstract][Full Text] [Related]
17. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
Liu Y; Zhang Y; Li Q; Xu R; Huang N
Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
[TBL] [Abstract][Full Text] [Related]
18. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
19. Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR.
Hou Z; Wang Y; Xia N; Lv T; Yuan X; Song Y
Cancer Sci; 2021 Jan; 112(1):275-286. PubMed ID: 33179318
[TBL] [Abstract][Full Text] [Related]
20. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
